Show simple item record

dc.contributor.authorHadjipanagi, Despinaen
dc.contributor.authorChrysanthou, S.en
dc.contributor.authorVoskarides, Konstantinosen
dc.contributor.authorConstantinou-Deltas, Constantinos D.en
dc.creatorHadjipanagi, Despinaen
dc.creatorChrysanthou, S.en
dc.creatorVoskarides, Konstantinosen
dc.creatorConstantinou-Deltas, Constantinos D.en
dc.date.accessioned2019-11-04T12:50:41Z
dc.date.available2019-11-04T12:50:41Z
dc.date.issued2014
dc.identifier.issn1756-0500
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/53121
dc.description.abstractBackground: Two variants in the gene encoding the cytochrome P450 2C9 enzyme (CYP2C9) are considered the most significant genetic risk factors associated with bleeding after warfarin prescription. A variant in the vitamin K epoxide reductase (VKORC1) has been also associated by several studies with warfarin response. Another variant in the P450 3A5 enzyme (CYP3A5) gene is known to affect the metabolism of many drugs, including tacrolimus. Findings. We conducted a population genetic study in 148 unrelated healthy Greek-Cypriot volunteers (through PCR-RFLP assays), in order to determine the frequencies of the above pharmacogenetics variants and to compare allele frequencies with those in other major ethnic groups. The allele frequencies of CYP2C9*2, CYP2C9*3 and CYP3A5*3 were found to be 0.162, 0.112 and 0.943 respectively, whereas VKORC1 - 1639A was 0.534. The latter frequency differs significantly when compared with Caucasians, Asians and Africans (p < 0.001) and is still significant when compared with the geographically and culturally closely related to Greek-Cypriots, Hellenes of Greece (p = 0.01). Interestingly ∼18% of our population are carriers of four or three risk alleles regarding warfarin sensitivity, therefore they have a high predisposition for bleeding after taking high or even normal warfarin doses. Conclusions: Our data show no significant difference in the frequency of CYP2C9 and CYP3A5 allelic variants when compared to the Caucasian population, but differ significantly when compared with Africans and Asians (p < 0.001). Also, the frequency of variant VKORC1 - 1639A differs between Greek-Cypriots and every other population we compared. Finally, about 1/5 Greek-Cypriots carry three or four risk alleles and ∼50% of them carry at least two independent risk alleles regarding warfarin sensitivity, a potentially high risk for over-anticoagulation. © 2014 Hadjipanagi et al.en
dc.description.abstractlicensee BioMed Central Ltd.en
dc.sourceBMC Research Notesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84898549380&doi=10.1186%2f1756-0500-7-123&partnerID=40&md5=6a2bc6f8da7d8b04925692b0012ef113
dc.subjectCyprusen
dc.subjectGreeceen
dc.subjectarticleen
dc.subjecthumanen
dc.subjectHumansen
dc.subjectadulten
dc.subjectwarfarinen
dc.subjectmaleen
dc.subjectgene frequencyen
dc.subjectgenotypeen
dc.subjectgenetic polymorphismen
dc.subjectGenetic Predisposition to Diseaseen
dc.subjectRisk Factorsen
dc.subjectrisk factoren
dc.subjectyoung adulten
dc.subjectgenetic predispositionen
dc.subjectgeneticsen
dc.subjectpolymerase chain reactionen
dc.subjectrestriction fragment length polymorphismen
dc.subjectcytochrome P450 3Aen
dc.subjectadverse drug reactionen
dc.subjectethnologyen
dc.subjectPolymorphism, Geneticen
dc.subjectPolymorphism, Restriction Fragment Lengthen
dc.subjectAryl Hydrocarbon Hydroxylasesen
dc.subjectCYP2C9en
dc.subjectCYP2C9 protein, humanen
dc.subjectCYP3A5en
dc.subjectCYP3A5 protein, humanen
dc.subjectCytochrome P-450 CYP3Aen
dc.subjectDrug-Related Side Effects and Adverse Reactionsen
dc.subjectGreek-Cypriotsen
dc.subjectPharmacogeneticsen
dc.subjectPopulation geneticsen
dc.subjecttacrolimusen
dc.subjectunspecific monooxygenaseen
dc.subjectvitamin K epoxide reductaseen
dc.subjectVitamin K Epoxide Reductasesen
dc.subjectVKORC1en
dc.subjectVKORC1 protein, humanen
dc.titleGenetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot populationen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/1756-0500-7-123
dc.description.volume7
dc.author.facultyΣχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences
dc.author.departmentΤμήμα Βιολογικών Επιστημών / Department of Biological Sciences
dc.type.uhtypeArticleen
dc.description.notes<p>Cited By :3</p>en
dc.source.abbreviationBMC Res.Notesen
dc.contributor.orcidConstantinou-Deltas, Constantinos D. [0000-0001-5549-9169]
dc.gnosis.orcid0000-0001-5549-9169


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record